Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1347858/000155837020012703/xxii-20200930x10q.htm
January 2023
November 2022
November 2022
November 2022
September 2022
September 2022
August 2022
July 2022
June 2022
June 2022
Exhibit 99.1
22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020
Key Highlights:
· | Net sales revenue increased approximately 11% to $6.4 million |
· | Gross profit continues to show improvement year-over-year as a result of targeted actions to improve margins and cost structure |
· | Operating loss improved by approximately $276 thousand |
· | Adjusted EBITDA improved 21% |
· | Appointed new CEO, James A. Mish and new CFO, John Franzino |
WILLIAMSVILLE, N.Y., August 6, 2020 (Globe Newswire) — 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding, today reported results for the second quarter ended June 30, 2020.
“Despite the unprecedented challenges brought on by COVID-19, I am pleased to report net sales revenue of $6.4 million for the second quarter of 2020, up 11% from the prior year, continued gross profit margin expansion, and improved operating loss. These results demonstrate our ability to execute on our initiatives to improve our margins and cost structure. Our financial position remains strong and we will continue to operate with strict cost controls, allocate our resources efficiently, and deploy capital where we believe it will give us the greatest return on our investments,” said James A. Mish, Chief Executive Officer of 22nd Century Group.
“With the comment period now closed on our Modified Risk Tobacco Product Application, the team is laser focused on setting the stage for a successful VLN® launch upon the authorization of our MRTP Application by the FDA. I am exceedingly proud of the dedication and tremendous progress the team has made so far this year and believe we are well positioned to capitalize on the many opportunities ahead,” Mish added.
Business Highlights and Notable Events:
· | The Company appointed James A. Mish as its Chief Executive Officer, effective June 22, and John Franzino as its Chief Financial Officer, effective June 3. Mish has extensive global executive leadership experience leading science-driven organizations with a focus on the development, manufacturing, and commercialization of active pharmaceutical ingredients (“API”), including cannabinoids, and related consumer products. Franzino has extensive financial leadership experience in the tobacco and alcoholic beverage industries. Mish is reviewing the Company’s current strategy and objectives and is expected to provide an update in November during the Company’s third quarter earnings call. |
· | The public comment period for the Company’s Modified Risk Tobacco Product (“MRTP”) Application for VLN® closed on May 18, 2020. The application requests a modified exposure designation from the FDA to market the Company’s proprietary reduced nicotine content tobacco cigarettes in the U.S. under the proposed brand name of VLN® with product labeling and advertising claims stating that VLN® has 95% less nicotine than conventional cigarettes, as well as other claims related to reduced nicotine exposure. The closing of the public comment period marks an important milestone in the FDA’s ongoing scientific review of the Company’s MRTP Application. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1347858/000155837020012703/xxii-20200930x10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by 22Nd Century Group, Inc..
22Nd Century Group, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More![]()
The decrease was primarily due to amortization expense on a lower patent base which resulted from one-time impairment charges as described in the "Impairment expense" section above.
These increases were partially offset by lower equity compensation expense of $1,127, lower one-time severance expenses of $415, a decrease in investor relations expenses of $140, a decrease in travel and entertainment expenses of $137, and a decrease in legal fees of $30.
27 Amounts in thousands, except for share and per-share data The increase in sales revenue for the three and nine months ended September 30, 2020, compared the three months ended September 30, 2019, was primarily the result of increases in the sales of contract manufactured filtered cigars and cigarettes.
Year-to-date, gross profit improved by $1.1 million year-over-year and continues to show improvement as a result of increased contract manufacturing operation (CMO) sales volume and pricing as well as targeted actions to improve production costs.
Our financial position remains strong with cash, cash equivalents, and short-term investment securities totaling approximately $26.8 million at the end of the third quarter 2020.
During the conference, 22nd Century...Read more
We must successfully execute our...Read more
We intend to build upon...Read more
The increase in cash used...Read more
Interest expense for the nine...Read more
Important factors that could cause...Read more
The YTD filtered cigar sales...Read more
32 We have an effective...Read more
To reflect this difference in...Read more
? We have refocused our...Read more
For the three and nine...Read more
The YTD period for 2020...Read more
? Quarter-to-date, total operating expenses...Read more
We have received extremely positive...Read more
Net loss The decrease in...Read more
MRTP expenses for both the...Read more
We recorded an unrealized gain...Read more
For the nine months ended...Read more
Net cash provided by (used...Read more
28 Personnel expense decreased by...Read more
We continue to maintain a...Read more
Lower R&D expense for three...Read more
Filtered cigar sales increased by...Read more
The decrease in sales, general...Read more
We have deployed this incremental...Read more
Unrealized gain (loss) on investment...Read more
The increase in SG&A expense...Read more
We continue to target and...Read more
These increased cash inflows were...Read more
The COVID-19 pandemic has caused...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
22Nd Century Group, Inc. provided additional information to their SEC Filing as exhibits
Ticker: XXII
CIK: 1347858
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-20-012703
Submitted to the SEC: Thu Nov 05 2020 7:23:48 AM EST
Accepted by the SEC: Thu Nov 05 2020
Period: Wednesday, September 30, 2020
Industry: Cigarettes